Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-12-01-2011
- Volume 23
- Issue 12
Contract API Manufacturing: The Year in Review
Expansion activity was limited as fine-chemical producers and CMOs of API and intermediates grapple with changing industry fundamentals.
By Patricia van Arnum
The year 2011 was another year of transition for fine-chemical producers and contract manufacturers of APIs and intermediates. As the pharmaceutical industry as a whole deals with slowing growth, increased generic-drug incursion, reduced R&D productivity, and the financing pinch for smaller and emerging bio/pharmaceutical companies, so do its suppliers. Expansion activity among fine-chemical producers and contract API manufacturers was limited although certain areas, such as high-potency manufacturing, continue to attract investment as do biopharmaceutical manufacturing and related services.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
almost 14 years ago
Mitigating Personnel Risksalmost 14 years ago
The Impact Of Single-Use Systemsalmost 14 years ago
Contamination: Invisible And Airbornealmost 14 years ago
Avoiding Contamination Risks in Aseptic Processesalmost 14 years ago
Choosing Cleanroom Clothingalmost 14 years ago
The Employment Outlook Brightensalmost 14 years ago
It’s déjà vu all over againalmost 14 years ago
Newsalmost 14 years ago
The Development of a Floating Drug-Delivery System for Metronidazolealmost 14 years ago
Impact of AgeingNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
